APA (7th ed.) Citation

Baraliakos, X., Poddubnyy, D., Hammel, L., Heyne, M., Veit, J., & Jentzsch, C. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: Protocol for a randomised open-label phase III study, AScalate. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Baraliakos, Xenofon, Denis Poddubnyy, Ludwig Hammel, Marvin Heyne, Justyna Veit, and Claudia Jentzsch. Treat-to-target Strategy with Secukinumab as a First-line Biological Disease Modifying Anti-rheumatic Drug Compared to Standard-of-care Treatment in Patients with Active Axial Spondyloarthritis: Protocol for a Randomised Open-label Phase III Study, AScalate. BMJ Publishing Group.

MLA (9th ed.) Citation

Baraliakos, Xenofon, et al. Treat-to-target Strategy with Secukinumab as a First-line Biological Disease Modifying Anti-rheumatic Drug Compared to Standard-of-care Treatment in Patients with Active Axial Spondyloarthritis: Protocol for a Randomised Open-label Phase III Study, AScalate. BMJ Publishing Group.